Publications
BMT CTN investigators have published >135 manuscripts, including >30 primary study results papers, in numerous peer-reviewed journals, including the New England Journal of Medicine, Journal of Clinical Oncology, and Blood. Selected publications are summarized for dissemination to patients and the lay public.
Note: Some Publications were unable to be listed below - please see that listing here. All other publications based on PubMedIDs are listed below.
Found 126 results
Filters: Keyword is Humans [Clear All Filters]
“Are We Making PROGRESS in Preventing Graft-versus-Host Disease and Improving Clinical Outcomes? Impact of BMT CTN 1301 Study Results on Clinical Practice.”, Transplant Cell Ther, vol. 28, no. 8, pp. 419-425, 2022.
, “Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis, Blood and Marrow Transplant Clinical Trials Network 1101Open for Accrual June 2012Open for Accrual June 2012.”, Transplant Cell Ther, vol. 28, no. 7, pp. 406.e1-406.e6, 2022.
, “Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT).”, Blood Cancer J, vol. 12, no. 2, p. 27, 2022.
, “Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma.”, Transplant Cell Ther, vol. 28, no. 8, pp. 446-454, 2022.
, “Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies.”, J Clin Oncol, vol. 40, no. 4, pp. 356-368, 2022.
, “Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.”, N Engl J Med, vol. 387, no. 2, pp. 132-147, 2022.
, “Two-sample survival probability curves: A graphical approach for the analysis of time to event data in clinical trials.”, Contemp Clin Trials, vol. 115, p. 106707, 2022.
, “Umbilical Cord Blood or HLA-Haploidentical Transplantation: Real-World Outcomes versus Randomized Trial Outcomes.”, Transplant Cell Ther, vol. 28, no. 2, pp. 109.e1-109.e8, 2022.
, “The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma.”, Transplant Cell Ther, vol. 27, no. 10, pp. 807-816, 2021.
, “Acute GVHD Diagnosis and Adjudication in a Multicenter Trial: A Report From the BMT CTN 1202 Biorepository Study.”, J Clin Oncol, vol. 39, no. 17, pp. 1878-1887, 2021.
, “Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome.”, J Clin Oncol, vol. 39, no. 30, pp. 3328-3339, 2021.
, “Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year.”, Transplant Cell Ther, vol. 27, no. 11, pp. 885-907, 2021.
, “Building a Fit for Purpose Clinical Trials Infrastructure to Accelerate the Assessment of Novel Hematopoietic Cell Transplantation Strategies and Cellular Immunotherapies.”, J Clin Oncol, vol. 39, no. 5, pp. 534-544, 2021.
, “Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial.”, Blood, vol. 137, no. 3, pp. 420-428, 2021.
, “Engraftment of Double Cord Blood Transplantation after Nonmyeloablative Conditioning with Escalated Total Body Irradiation Dosing to Facilitate Engraftment in Immunocompetent Patients.”, Transplant Cell Ther, vol. 27, no. 10, pp. 879.e1-879.e3, 2021.
, “Hematopoietic Cell Transplantation: Practice Predictions for the Year 2023.”, Transplant Cell Ther, vol. 27, no. 2, pp. 183.e1-183.e7, 2021.
, “Immune Recovery Following Autologous Hematopoietic Stem Cell Transplantation in HIV-Related Lymphoma Patients on the BMT CTN 0803/AMC 071 Trial.”, Front Immunol, vol. 12, p. 700045, 2021.
, “International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.”, Leukemia, vol. 35, no. 1, pp. 18-30, 2021.
, “Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial.”, Transplant Cell Ther, vol. 27, no. 6, pp. 483.e1-483.e6, 2021.
, “Using increased trust in medical researchers to increase minority recruitment: The RECRUIT cluster randomized clinical trial.”, Contemp Clin Trials, vol. 109, p. 106519, 2021.
, “Analysis of the Whole CDR3 T Cell Receptor Repertoire after Hematopoietic Stem Cell Transplantation in 2 Clinical Cohorts.”, Biol Blood Marrow Transplant, vol. 26, no. 6, pp. 1050-1070, 2020.
, “Follistatin and Soluble Endoglin Predict 1-Year Nonrelapse Mortality after Allogeneic Hematopoietic Cell Transplantation.”, Biol Blood Marrow Transplant, vol. 26, no. 3, pp. 606-611, 2020.
, “Group sequential tests for treatment effect on survival and cumulative incidence at a fixed time point.”, Lifetime Data Anal, vol. 26, no. 3, pp. 603-623, 2020.
, “Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease.”, J Clin Oncol, vol. 38, no. 12, pp. 1273-1283, 2020.
, “Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation.”, Bone Marrow Transplant, vol. 55, no. 9, pp. 1810-1816, 2020.
,